Chardan Capital Sticks to Their Hold Rating for Vascular Biogenics (VBLT)

By Austin Angelo

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Hold rating on Vascular Biogenics (VBLTResearch Report), with a price target of $3. The company’s shares closed yesterday at $1.21.

Livshits observed:

“We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin.”

According to, Livshits is a 1-star analyst with an average return of -5.3% and a 25.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.

Vascular Biogenics has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.10 and a one-year low of $0.60. Currently, Vascular Biogenics has an average volume of 114.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.